Similar first-generation CAR designs were successfully used in subsequent studies with NK-92 cells targeting the B-cell differentiation antigens CD19 and CD20 (48–53), CD138 for recognition of multiple myeloma (54), and various surface antigens expressed by solid tumors including the disialoganglioside GD2, epithelial cell adhesion molecule (EpCAM), and a peptide epitope of the melanoma antigen gp100 in complex with HLA-A2 (55–59) (Table 1). This evidence concerns the gene EPCAM and plasma cell myeloma.